My ePortfolio Register   

Device hits pancreatic tumours hard with toxic 4-drug cocktail, sparing the body

A highly lethal cancer sometimes requires large doses of highly toxic drugs.

However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects.

Now a powerhouse team of researchers at the University of North Carolina at Chapel Hill has revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumours to stunt their growth or in some cases, shrink them - all while showing signs that the rest of the body would be spared toxic side effects.

"We use the device to hit the primary tumour hard," said UNC Lineberger Comprehensive Cancer Center member Jen Jen Yeh, M.D., who is also an associate professor in the department of pharmacology and the UNC School of Medicine department of surgery.

"It's an exciting approach because there is so little systemic toxicity that it leaves room to administer additional drugs against cancer cells that may have spread in the rest of the body."

The work, published in the Proceedings of the National Academy of Sciences, highlights the cocktail FOLFIRINOX, a combination of four chemotherapy drugs that has been shown to shrink tumours or halt their growth in nearly a third of pancreatic cancer patients.

It's one of today's first-line treatments for pancreatic cancer, but it is not suitable for all patients due to its degree of toxicity when delivered through the bloodstream.

The new device, currently tested in mice, delivers the drugs directly to the tumour, providing a viable alternative to sending this toxic cocktail through the bloodstream, limiting harsh effects throughout the rest of the body.

"We are striving to get our device into clinical trials within the next several years," said Joseph M. DeSimone, Chancellor's Eminent Professor of Chemistry in UNC's College of Arts and Sciences and William R. Kenan, Jr. Distinguished Professor of Chemical Engineering at NC State University.

"The prospect of halting tumour growth with our device, and potentially shrinking tumours, could help more patients qualify for surgery."

Surgically removing a tumour is currently the best chance of cure for patients with pancreatic cancer, but only 15 percent of patients have operable tumours.

The findings are the latest for the researchers in the testing of the implantable device, which uses electric fields to drive the chemotherapy drugs directly into tumours.

In a study published last year in Science Translational Medicine, the team showed, for the first time in animal models, that the device could be implanted on top of pancreatic tumours to increase the amount of the cancer drug gemcitabine reaching them.

The tumours stopped growing and shrunk, providing more favourable conditions to remove the tumour and cure the disease.

The discovery was hailed as a big advance for the treatment of pancreatic cancer, which has a 75 percent mortality rate within a year of diagnosis - a statistic that has not changed in more than 40 years.

The latest study builds on last year's critical advance.

Like the previous study, the device increased the amount of drug reaching the tumours, lowered drug concentration in the blood and significantly impacted tumour growth compared to intravenous delivery of the same drugs.

But this time, the device was used with a more potent four-drug combination, making the treatment more effective while limiting unbearable side effects.

The accumulation of drug in the tumour using the device was at least three times greater than when using IV administration.

"The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body," said James D. Byrne, Ph.D., the paper's first author and a current medical student at the UNC School of Medicine.

"If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments."

Source: University Of North Carolina At Chapel Hill



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence